Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $500.6152W HIGH $769.98
Volume
234.16 K
Value Traded
345.19 M
Short % Float
2.46%
Days to Cover
3.6
-3.33%Week
+4.58%1 Month
-2.93%3 Month
-2.12%6 Month
+3.12%5 Year
+59,072.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
50.87 B
EPS (TTM)
14.47
P/E Ratio
38.10
Ent. Value
43.68 B
Total Shares
78.80 M
Float Shares
78.48 M
Insiders
0.38%
Institutions
97.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
IDXX Catalyst Timeline
Dated clinical, regulatory and corporate events for IDEXX Laboratories, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IDEXX Laboratories, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How IDXX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
IDEXX Laboratories, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IDXX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kingsley Lawrence DDirector | Option | 2,203 11,771 held | $114.17 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IDXX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.9 % (-40 %) | 8.43 M | 15.00 K | 59.78% ( 5.61 K) |
Ownership Trends
IDXX Short Interest
Shares sold short, counted twice a month.
2.46%
Short % of Float
of tradable shares sold short
1.9M
Shares Sold Short
-0.6% vs prior count
3.6 Moderate
Days to Cover
trading days of normal volume to buy every short share back
532.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IDXX ranks across every disease it competes in
Competitive Position is a premium feature
See how IDXX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIDXX News
IDXX▲ +18.3%today
IDEXX Laboratories Announces Third Quarter Results
IDEXX Laboratories reported a 10% revenue growth in Q3 2026, reaching $1,214 million. Earnings per share rose 18% to $4.01, reflecting strong performance in the Companion Animal Group. The company raised its revenue guidance for 2026 to between $4,741 million and $4,767 million, driven by robust recurring revenue growth. Innovations and successful integration of CoVet contributed to this positive outlook.
Read more →IDXXIDEXX Laboratories to Release 2026 Third Quarter Financial Results
IDEXX Laboratories, Inc. has announced the release date for its 2026 third quarter financial results, set for November 2, 2026. The company will host an analyst conference call at 8:30 a.m. ET on the same day. Investors and analysts can access a live webcast and a transcript of the prepared remarks.
Read more →IDXXChicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
Chicago Pacific Founders announced the exit of its investment in CoVetAI following its acquisition by IDEXX Laboratories. CoVetAI, known for its AI-powered clinical scribe platform, is seen as a significant player in veterinary technology. The acquisition underscores the importance of AI tools in enhancing veterinary practices and patient care. Financial details of the transaction remain undisclosed.
Read more →IDXXIDEXX erweitert den Fecal Dx Antigentest um den Nachweis von Taeniid-Bandwürmern
IDEXX Laboratories has announced an expansion of its Fecal Dx Antigentest in Germany to include the detection of Taeniid tapeworms, such as Taenia and Echinococcus spp. This enhancement allows the test to identify intestinal parasite infections at an earlier stage, demonstrating up to double the detection rate compared to traditional flotation methods.
Read more →IDXXIDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
IDEXX Laboratories has expanded its Faecal Dx antigen testing platform in the UK to include taeniid tapeworm detection. This enhancement allows for the detection of more intestinal parasites, improving diagnostic capabilities for veterinarians. The platform now identifies seven clinically relevant intestinal parasite groups, aiding in better pet healthcare.
Read more →IDXXIDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
IDEXX Laboratories has announced the acquisition of CoVetAI, aiming to enhance veterinary workflow intelligence. This strategic move is expected to bolster IDEXX's offerings in the veterinary market, reflecting their commitment to innovation and improved services for veterinary professionals.
Read more →IDXXIDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories, a leader in pet healthcare, announced participation in the Morgan Stanley 24th Annual Global Healthcare Conference. CEO Mike Erickson and CFO Andrew Emerson will engage in a fireside chat on September 14, 2026. This event will be accessible via a live audio webcast, enhancing investor engagement.
Read more →IDXXIDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories launched the Catalyst proBNP Test, the first dual-species NT-proBNP test for cats and dogs. This in-clinic test enhances cardiac assessment capabilities, providing real-time results during veterinary visits. The test aims to improve early detection of heart disease, which affects many pets, and is expected to be available in North America by October 2026.
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results
IDEXX Laboratories reported a strong performance in its second quarter of 2026, with total revenues reaching $1,217 million. The growth was primarily driven by a 9% increase in the Companion Animal Group and a notable 15% rise in Water revenue. This positive trend reflects the company's robust position in the pet healthcare market.
Read more →IDXXIDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
IDEXX Laboratories, Inc. has released its 2025 Corporate Responsibility Report, showcasing its progress in innovation, employee engagement, and environmental sustainability. The report highlights advancements in veterinary diagnostics, including new cancer detection capabilities, and IDEXX's commitment to social initiatives benefiting underserved communities. The company also emphasizes its efforts in reducing its environmental footprint and enhancing operational efficiency.
Read more →IDXXIDEXX Laboratories to Release 2026 Second Quarter Financial Results
IDEXX Laboratories is set to announce its financial results for the second quarter of 2026. The release will provide insights into the company's performance and financial health during this period. Investors and stakeholders are likely to closely monitor these results for future guidance.
Read more →IDXXIDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
IDEXX Laboratories has expanded its Fecal Dx antigen testing platform to include taeniid tapeworm detection. This enhancement allows for the detection of more intestinal parasites, improving early treatment options for pets. The platform has seen significant adoption since its launch, with over 50 million tests conducted globally. The new testing feature will be available at no extra cost to IDEXX Reference Laboratories customers in the U.S. and Canada starting in late June.
Read more →IDXXIDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
IDEXX Laboratories announced the integration of SDMA, a renal biomarker, into Catalyst CLIPs, enhancing kidney function evaluations for pets. This feature will be available in June for U.S. and Canadian customers, allowing veterinarians to detect kidney issues earlier. The integration aims to improve pet health outcomes and streamline veterinary workflows.
Read more →IDXXIDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
IDEXX Laboratories has announced its participation in the upcoming Stifel Conference and also revealed plans for an Investor Day in 2026. This event aims to engage with investors and provide insights into the company's future strategies and developments. Further details about the conference and Investor Day are anticipated.
Read more →IDXXIDEXX Laboratories Announces First Quarter Results
IDEXX Laboratories recently announced its first quarter results, but the article does not provide any details regarding the financial performance or key metrics. The lack of information leaves stakeholders without insights into the company's current status. Overall, the announcement appears to be underwhelming due to the absence of critical data.
Read more →IDXXIDEXX Laboratories to Release 2026 First Quarter Financial Results
IDEXX Laboratories is set to announce its financial results for the first quarter of 2026. The release will provide insights into the company's performance during this period. Further details regarding the results and any potential implications for stakeholders are anticipated.
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
IDEXX Laboratories reported robust financial results for Q4 and full year 2025, with revenues reaching $1,091 million, a 14% increase year-over-year. The Companion Animal Group drove growth, supported by innovations like IDEXX Cancer Dx. The company anticipates continued growth into 2026, projecting revenues between $4.632 billion and $4.720 billion.
Read more →IDXXLowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus
IDEXX Laboratories has launched the ImageVue DR50 Plus, a cutting-edge digital imaging system for veterinary practices. This system significantly reduces radiation exposure while providing high-definition, AI-powered imaging. It aims to enhance diagnostic accuracy and workflow efficiency, particularly benefiting veterinary teams and their patients. The system is now available in the U.S. and Canada.
Read more →IDXXIDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs
IDEXX Laboratories is set to enhance veterinary cancer diagnostics with the inclusion of mast cell tumor detection in its Cancer Dx Panel by mid-2026. This addition, along with the rollout of FNA cytology on the inVue Dx analyzer, aims to provide rapid, in-clinic results for veterinarians. These advancements are expected to improve early detection and treatment decisions for canine cancers.
Read more →IDXXIDEXX Announces CEO Succession
IDEXX Laboratories has announced the promotion of Michael Erickson to President and CEO, effective May 12, 2026. Jonathan Mazelsky will transition to Executive Chair and retire after the 2027 annual meeting. The leadership change is part of a planned succession, with both leaders emphasizing IDEXX's commitment to innovation and growth in veterinary healthcare.
Read more →About IDEXX Laboratories, Inc.
HeadquartersONE IDEXX DRIVE, WESTBROOK, ME, 04092-2041
BIOPHARMAWATCH ELITE PLUS
Trade the next IDXX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime